Research programme: spinal muscular atrophy therapies - Spotlight Innovation

Drug Profile

Research programme: spinal muscular atrophy therapies - Spotlight Innovation

Alternative Names: STL-182

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University School of Medicine; The Laboratory for Drug Discovery in Neurodegeneration
  • Developer Indiana University School of Medicine
  • Class Small molecules
  • Mechanism of Action SMN complex protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Spinal muscular atrophy

Most Recent Events

  • 16 Aug 2017 Spotlight Innovation entered into a research agreement with Indiana University to develop spinal muscular atrophy therapies
  • 30 Jun 2017 Spotlight Innovation entered into a research agreement with Brigham and Women's Hospital to develop spinal muscular atrophy therapies
  • 19 Oct 2016 SLT 182 licensed to Spotlight Innovation worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top